Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin

Inclusion Criteria

- Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or
recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic
oligodendroglioma.

- Evidence of measurable recurrent or residual primary CNS neoplasm.

- An interval of at least 3 weeks between prior surgical resection or 6 weeks between
prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is
unequivocal evidence of tumor progression after surgery, radiotherapy, or
chemotherapy.

- Hematocrit > 29%, ANC > 1,500, platelets > 125,000

- Serum creatinine < 1.5 mg/dl, BUN < 25 mg/dl, serum SGOT and bilirubin < 1.5 times
upper limit of normal

- Negative pregnancy test for female patients